SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA
(Thomson Reuters ONE) -
More than 35 presentations and sessions showcase Shire's gene therapy pipeline
and leading factor portfolio
Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading
biotechnology company focused on serving individuals with rare diseases, will
present research covering a broad range of rare bleeding disorders at the 26th
Biennial International Society on Thrombosis and Haemostasis Congress (ISTH),
July 8-13, 2017 in Berlin, Germany. Showcased in eight oral presentations, 29
poster presentations and three symposia, these data underscore Shire's pursuit
of treatment innovation rooted in safety, efficacy, and individualized care for
hemophilia patients.
"As the global leader in rare hematology with over 70 years of expertise, Shire
is proud to showcase the depth of our hemophilia portfolio and the latest data
reinforcing the proven safety and efficacy of our products," said Bruce
Ewenstein, M.D., Ph.D., VP Clinical Development for Hematology at Shire. "In
addition, we look forward to presenting new research in gene therapy and a novel
patient-reported outcome measure that may help patients individualize their
hemophilia treatment goals."
Advancing the Promise of Gene Therapy in Hemophilia
Throughout ISTH, Shire will present 11 scientific updates regarding its gene
therapy pipeline, which shows promise for both hemophilia A and B populations.
The goal of gene therapy is to enable a hemophilia patient's body to naturally
produce a sufficient amount of the missing factor VIII or IX to alleviate
bleeding episodes.(1) Therefore, it may be possible to help convert a hemophilia
patient's bleeding phenotype from severe to mild or even normal in some
cases.(2) Notably, Shire will showcase the following new data presentations on
the development of SHP654 for the treatment of hemophilia A.
* Development of SHP654, a highly efficient AAV8-based BDD-FVIII gene therapy
vector for treatment of hemophilia A. Session Title: Gene Therapy for
Hemophilia: Clinical. Oral #OC 13.6.10th July, 17:45-19:00 CEST; Hall B(3)
* Integration site analysis in mice demonstrates excellent biosafety profile
of a recombinant (r) FVIII adeno-associated virus (AAV8) gene therapy
product Session Title: Poster Session. Poster #PB 1094. 11th July,
12:00-13:15 CEST, Exhibition Hall 4.2(4)
In addition, Shire will give an oral presentation on its gene therapy technology
for hemophilia B:
* SHP648: A high performing next generation FIX gene therapy vector based on
AAV8 Session Title: Gene Therapy for Hemophilia: Preclinical. Oral# OC
62.2. 12th July, 09:30-10:45 CEST, Helsinki 1(5)
Paving a Frontier in Patient-Centered Care in Hemophilia
Shire will present new data on its novel patient-reported outcome measure, Goal
Attainment Scale for Hemophilia (GAS-Hem). GAS-Hem is intended to support
advanced hemophilia care by supplementing standard clinical outcome measures
with those that are patient-centered, customizable, and sensitive to change
within individual patients and across patient populations.(6) Patient goals are
identified and agreed upon together and can span various goal areas, such as
managing hemophilia complications and impact on life. Results of a 12-week study
of 42 patients aged 5-65 years of age with hemophilia A or B on prophylaxis
treatment suggest that GAS-Hem is successfully uncovering outcome measures not
captured by currently available tools.(6)
* Responsiveness and construct validity of Goal Attainment Scaling for
Hemophilia (GAS-Hem): a novel, personalised, patient-reported outcome for
haemophilia, Session Title: Poster Session. Poster #PB 203. 10th July,
12:00-13:15 CEST, Exhibition Hall 2.2.(6)
About Hemophilia
Hemophilia is a challenging chronic disease that causes longer-than-normal
bleeding due to absent or deficient clotting factor in the blood.(7) Hemophilia
A is more common than hemophilia B;(7) hemophilia A affects about 150,000
people, whereas hemophilia B affects about 30,000 people worldwide.(8)
People with hemophilia, working closely with their healthcare professionals, can
live healthy lives with proper care and adequate treatment.(9) Treatment
regimens typically include on-demand and/or regular prophylactic infusions of
factor replacement therapy to control or prevent the risk of bleeding.(7,10)
Inhibitors are a serious complication in patients with hemophilia.(11) They form
when the body's immune system attacks the proteins in factor therapy, causing it
to be ineffective.(11) Immune tolerance induction and bypassing agents are
essential therapies for this patient population that help either train the body
to tolerate the factor concentrate or bypass the inhibitor to help the body form
a clot and stop bleeding.(9,11,12)
References
1. National Institutes of Health: National Heart, Lung and Blood Institute.
"Gene Therapy Helps Patients With Hemophilia B." National Heart, Lung and
Blood Institute website.
https://www.nhlbi.nih.gov/news/enewsletter/professional/ProfHemophilia-
article Accessed May 31, 2017.
2. Amit et al. "Adenovirus-Associated Virus Vector-Mediated Gene Transfer in
Hemophilia B." N Engl J Med. 2011 Dec 22; 365(25): 2357-2365. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265081/. Accessed May
31, 2017.
3. Falkner et al. "Development of SHP654 a highly efficient AAV8-based BDD-
FVIII gene therapy vector for treatment of hemophilia A." International
Society on Thrombosis and Haemostasis Congress. Berlin, Germany July
8-13, 2017. Available at:
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2475-0379
4. Hoellriegl et al. "Integration site analysis in mice demonstrates excellent
biosafety profile of a recombinant ® FVIII adeno-associated virus (AAV8)
gene therapy product." International Society on Thrombosis and Haemostasis
Congress. Berlin, Germany July 8-13, 2017. Available at:
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2475-0379
5. Horling et al. "SHP648: A high performing next generation FIX gene therapy
vector based on AAV8." International Society on Thrombosis and Haemostasis
Congress. Berlin, Germany July 8-13, 2017. Available at:
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2475-0379
6. Recht et al. "Responsiveness and construct validity of Goal Attainment
Scaling for Hemophilia (GAS-Hem): a novel, personalised, patient-reported
outcome for haemophilia." International Society on Thrombosis and
Haemostasis Congress. Berlin, Germany July 8-13, 2017. Available at:
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2475-0379
7. World Federation of Hemophilia. "What is hemophilia?" World Federation of
Hemophilia website. http://www.wfh.org/en/page.aspx?pid=646. Accessed
January 12, 2017
8. World Federation of Hemophilia. Report on the Annual Global Survey 2015.
World Federation of Hemophilia website.
http://www1.wfh.org/publication/files/pdf-1669.pdf. Accessed January
12, 2017.
9. World Federation of Hemophilia. "About Bleeding Disorders: Treatment."
World Federation of Hemophilia website.
http://www.wfh.org/en/page.aspx?pid=642. Accessed January 12, 2017.
10. National Hemophilia Foundation. "Hemophilia A". National Hemophilia
Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-
Bleeding-Disorders/Hemophilia-A. Accessed January 12, 2017.
11. World Federation of Hemophilia. "What are inhibitors?" World Federation of
Hemophilia website. http://www.wfh.org/en/page.aspx?pid=651. Accessed June
12, 2017.
12. Hemophilia Federation of America. "Treatment & Eradication of Inhibitors."
Hemophilia Federation of America website.
http://www.hemophiliafed.org/bleeding-disorders/inhibitors/treatment-
eradication-inhibitors/ Accessed June 12, 2017.
For further information, please contact:
Investor Relations
Ian Karp ikarp(at)shire.com +1 781 482 9018
Robert Coates rcoates(at)shire.com +44 1256 894874
Media
Molly Poarch molly.poarch(at)shire.com +1 312 965 3413
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with
rare diseases and other highly specialized conditions. We strive to develop
best-in-class products, many of which are available in more than 100 countries,
across core therapeutic areas including Hematology, Immunology, Neuroscience,
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine /
Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
http://www.shire.com
Forward-Looking Statements
Statements included herein that are not historical facts, including without
limitation statements concerning future strategy, plans, objectives,
expectations and intentions, the anticipated timing of clinical trials and
approvals for, and the commercial potential of, inline or pipeline products, are
forward-looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event such
risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited to,
the following:
* Shire's products may not be a commercial success;
* increased pricing pressures and limits on patient access as a result of
governmental regulations and market developments may affect Shire's future
revenues, financial condition and results of operations;
* Shire conducts its own manufacturing operations for certain of its products
and is reliant on third party contract manufacturers to manufacture other
products and to provide goods and services. Some of Shire's products or
ingredients are only available from a single approved source for
manufacture. Any disruption to the supply chain for any of Shire's products
may result in Shire being unable to continue marketing or developing a
product or may result in Shire being unable to do so on a commercially
viable basis for some period of time;
* the manufacture of Shire's products is subject to extensive oversight by
various regulatory agencies. Regulatory approvals or interventions
associated with changes to manufacturing sites, ingredients or manufacturing
processes could lead to, among other things, significant delays, an increase
in operating costs, lost product sales, an interruption of research
activities or the delay of new product launches;
* certain of Shire's therapies involve lengthy and complex processes, which
may prevent Shire from timely responding to market forces and effectively
managing its production capacity;
* Shire has a portfolio of products in various stages of research and
development. The successful development of these products is highly
uncertain and requires significant expenditures and time, and there is no
guarantee that these products will receive regulatory approval;
* the actions of certain customers could affect Shire's ability to sell or
market products profitably. Fluctuations in buying or distribution patterns
by such customers can adversely affect Shire's revenues, financial
conditions or results of operations;
* Shire's products and product candidates face substantial competition in the
product markets in which it operates, including competition from generics;
* adverse outcomes in legal matters, tax audits and other disputes, including
Shire's ability to enforce and defend patents and other intellectual
property rights required for its business, could have a material adverse
effect on the combined company's revenues, financial condition or results of
operations;
* inability to successfully compete for highly qualified personnel from other
companies and organizations;
* failure to achieve the strategic objectives, including expected operating
efficiencies, cost savings, revenue enhancements, synergies or other
benefits at the time anticipated or at all with respect to Shire's
acquisition of NPS Pharmaceuticals Inc., Dyax Corp. or Baxalta Incorporated
may adversely affect Shire's financial condition and results of operations;
* Shire's growth strategy depends in part upon its ability to expand its
product portfolio through external collaborations, which, if unsuccessful,
may adversely affect the development and sale of its products;
* a slowdown of global economic growth, or economic instability of countries
in which Shire does business, as well as changes in foreign currency
exchange rates and interest rates, that adversely impact the availability
and cost of credit and customer purchasing and payment patterns, including
the collectability of customer accounts receivable;
* failure of a marketed product to work effectively or if such a product is
the cause of adverse side effects could result in damage to Shire's
reputation, the withdrawal of the product and legal action against Shire;
* investigations or enforcement action by regulatory authorities or law
enforcement agencies relating to Shire's activities in the highly regulated
markets in which it operates may result in significant legal costs and the
payment of substantial compensation or fines;
* Shire is dependent on information technology and its systems and
infrastructure face certain risks, including from service disruptions, the
loss of sensitive or confidential information, cyber-attacks and other
security breaches or data leakages that could have a material adverse effect
on Shire's revenues, financial condition or results of operations;
* Shire incurred substantial additional indebtedness to finance the Baxalta
acquisition, which may decrease its business flexibility and increase
borrowing costs; and
a further list and description of risks, uncertainties and other matters can be
found in Shire's most recent Annual Report on Form 10-K and in Shire's
subsequent Quarterly Reports on Form 10-Q, in each case including those risks
outlined in "ITEM 1A: Risk Factors", and in subsequent reports on Form 8-K and
other Securities and Exchange Commission filings, all of which are available on
Shire's website.
All forward-looking statements attributable to us or any person acting on our
behalf are expressly qualified in their entirety by this cautionary statement.
Readers are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof. Except to the extent otherwise
required by applicable law, we do not undertake any obligation to update or
revise forward-looking statements, whether as a result of new information,
future events or otherwise.
###
S33038
6/17
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire Pharmaceuticals Group via GlobeNewswire
Datum: 23.06.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 549550
Anzahl Zeichen: 17374
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 289 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA"
steht unter der journalistisch-redaktionellen Verantwortung von
Shire Pharmaceuticals Group (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
